{"title":"新产品简介[aducanumab-avwa、阿维普地尔、甲磺酸贝鲁莫地尔、贝珠替凡(同类第一)、地西塔单抗韦多汀、多司他利单抗gxly、福祖洛帕利、hetrombopag-alcamin、ibrexafungerp、盐酸伊美格列明(同类第一","authors":"","doi":"10.1358/dot.2021.57.10.3369187","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New product intros [aducanumab-avwa, aviptadil, belumosudil mesylate, belzutifan (first-in-class), disitamab vedotin, dostarlimab-gxly, fuzuloparib, hetrombopag olamine, ibrexafungerp, imeglimin hydrochloride (first-in-class), infigratinib, Kconvac]\",\"authors\":\"\",\"doi\":\"10.1358/dot.2021.57.10.3369187\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":85144,\"journal\":{\"name\":\"Medicamentos de actualidad. Drugs of today\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicamentos de actualidad. Drugs of today\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1358/dot.2021.57.10.3369187\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2021.57.10.3369187","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
New product intros [aducanumab-avwa, aviptadil, belumosudil mesylate, belzutifan (first-in-class), disitamab vedotin, dostarlimab-gxly, fuzuloparib, hetrombopag olamine, ibrexafungerp, imeglimin hydrochloride (first-in-class), infigratinib, Kconvac]